Loading…

Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy

Background: Although prothrombin complex concentrate (PCC) is often used to counteract vitamin K antagonist (VKA) therapy, evidence regarding the optimal dose for this indication is lacking. In Dutch hospitals, either a variable dose, based on body weight, target INR (international normalised ratio)...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion medicine (Oxford, England) England), 2011-04, Vol.21 (2), p.116-123
Main Authors: Khorsand, N., Veeger, N. J. G. M., Muller, M., Overdiek, J. W. P. M., Huisman, W., van Hest, R. M., Meijer, K.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4060-b2390590f3fae166e872d65155d9d2332838dd1fc3e9092ee0f2ddbe8806d3ca3
cites cdi_FETCH-LOGICAL-c4060-b2390590f3fae166e872d65155d9d2332838dd1fc3e9092ee0f2ddbe8806d3ca3
container_end_page 123
container_issue 2
container_start_page 116
container_title Transfusion medicine (Oxford, England)
container_volume 21
creator Khorsand, N.
Veeger, N. J. G. M.
Muller, M.
Overdiek, J. W. P. M.
Huisman, W.
van Hest, R. M.
Meijer, K.
description Background: Although prothrombin complex concentrate (PCC) is often used to counteract vitamin K antagonist (VKA) therapy, evidence regarding the optimal dose for this indication is lacking. In Dutch hospitals, either a variable dose, based on body weight, target INR (international normalised ratio) and initial INR, or a fixed dose is used. Aim/objectives: In this observational, pilot study, the efficacy and feasibility of the fixed dose strategy compared to the variable dosing regimen, is investigated. Materials and Methods: Consecutive patients receiving PCC (Cofact®, Sanquin, Amsterdam) for VKA reversal because of a major non‐cranial bleed or an invasive procedure were enrolled in two cohorts. Data were collected prospectively in the fixed dose group, cohort 1, and retrospectively in the variable dose regimen, cohort 2. Study endpoints were proportion of patients reaching target INR and successful clinical outcome. Results: Cohort 1 consisted of 35 and cohort 2 of 32 patients. Target INR was reached in 70% of patients in cohort 1 versus 81% in cohort 2 (P = 0·37). Successful clinical outcome was seen in 91% of patients in cohort 1 versus 94% in cohort 2 (P = 1·00). Median INR decreased from 4·7 to 1·8 with a median dosage of 1040 IU factor IX (F IX) in cohort 1 and from 4·7 to 1·6 with a median dosage of 1580 IU F IX in cohort 2. Conclusion: This study suggests that a fixed dose of 1040 IU of F IX may be an effective way to rapidly counteract VKA therapy in our patient population and provides a basis for future research.
doi_str_mv 10.1111/j.1365-3148.2010.01050.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_852906991</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>852906991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4060-b2390590f3fae166e872d65155d9d2332838dd1fc3e9092ee0f2ddbe8806d3ca3</originalsourceid><addsrcrecordid>eNqNkE2P0zAQhi0EYsvCX0C-cUrxxzqxDxzQalvQduFSQOJiOfFk1yWJi-2U9N_jbJeesWTNjOd9Z6wHIUzJkubzfrekvBQFp1dyyUh-zVeQ5fQMLc6N52hBlJBFJSp5gV7FuCOEcqbYS3TBKKm4kGSBupWbwOIDhDhGfDDBmboDbH0E7Fu8Dz49BN_XbsCN7_cdTDkODQwpmAS49SHX45AgmCa54R4fXDJ9Vt9iMyRz7wcXE04Pub8_vkYvWtNFePMUL9G31c32-lOx-br-fP1xUzRXpCRFzbgiQpGWtwZoWYKsmC0FFcIqyzhnkktradtwUEQxANIya2uQkpSWN4Zfonenufn7v0eISfcuNtB1ZgA_Ri0FU6RUimalPCmb4GMM0Op9cL0JR02JnlHrnZ6J6pmonlHrR9R6yta3T0vGugd7Nv5jmwUfToI_roPjfw_W27ubOcv-4uTPBGE6-034pcuKV0L_-LLW32-3_OdqvdEb_hdiq54k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>852906991</pqid></control><display><type>article</type><title>Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy</title><source>Wiley</source><creator>Khorsand, N. ; Veeger, N. J. G. M. ; Muller, M. ; Overdiek, J. W. P. M. ; Huisman, W. ; van Hest, R. M. ; Meijer, K.</creator><creatorcontrib>Khorsand, N. ; Veeger, N. J. G. M. ; Muller, M. ; Overdiek, J. W. P. M. ; Huisman, W. ; van Hest, R. M. ; Meijer, K.</creatorcontrib><description>Background: Although prothrombin complex concentrate (PCC) is often used to counteract vitamin K antagonist (VKA) therapy, evidence regarding the optimal dose for this indication is lacking. In Dutch hospitals, either a variable dose, based on body weight, target INR (international normalised ratio) and initial INR, or a fixed dose is used. Aim/objectives: In this observational, pilot study, the efficacy and feasibility of the fixed dose strategy compared to the variable dosing regimen, is investigated. Materials and Methods: Consecutive patients receiving PCC (Cofact®, Sanquin, Amsterdam) for VKA reversal because of a major non‐cranial bleed or an invasive procedure were enrolled in two cohorts. Data were collected prospectively in the fixed dose group, cohort 1, and retrospectively in the variable dose regimen, cohort 2. Study endpoints were proportion of patients reaching target INR and successful clinical outcome. Results: Cohort 1 consisted of 35 and cohort 2 of 32 patients. Target INR was reached in 70% of patients in cohort 1 versus 81% in cohort 2 (P = 0·37). Successful clinical outcome was seen in 91% of patients in cohort 1 versus 94% in cohort 2 (P = 1·00). Median INR decreased from 4·7 to 1·8 with a median dosage of 1040 IU factor IX (F IX) in cohort 1 and from 4·7 to 1·6 with a median dosage of 1580 IU F IX in cohort 2. Conclusion: This study suggests that a fixed dose of 1040 IU of F IX may be an effective way to rapidly counteract VKA therapy in our patient population and provides a basis for future research.</description><identifier>ISSN: 0958-7578</identifier><identifier>EISSN: 1365-3148</identifier><identifier>DOI: 10.1111/j.1365-3148.2010.01050.x</identifier><identifier>PMID: 21073580</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject><![CDATA[Acenocoumarol - adverse effects ; Acenocoumarol - antagonists & inhibitors ; Adult ; Aged ; Aged, 80 and over ; Anticoagulants - adverse effects ; Anticoagulants - antagonists & inhibitors ; Antidotes - administration & dosage ; Antidotes - therapeutic use ; bleeding ; Blood Coagulation Factors - administration & dosage ; Blood Coagulation Factors - therapeutic use ; Cofact ; Cohort Studies ; Dose-Response Relationship, Drug ; Female ; Hemorrhage - chemically induced ; Hemorrhage - prevention & control ; Humans ; International Normalized Ratio ; Male ; Middle Aged ; Phenprocoumon - adverse effects ; Phenprocoumon - antagonists & inhibitors ; Prospective Studies ; prothrombin complex concentrate ; Retrospective Studies ; Vitamin K - antagonists & inhibitors ; vitamin K antagonist ; Warfarin - adverse effects ; Warfarin - antagonists & inhibitors]]></subject><ispartof>Transfusion medicine (Oxford, England), 2011-04, Vol.21 (2), p.116-123</ispartof><rights>2010 The Authors. Transfusion Medicine © 2010 British Blood Transfusion Society</rights><rights>2010 The Authors. Transfusion Medicine © 2010 British Blood Transfusion Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4060-b2390590f3fae166e872d65155d9d2332838dd1fc3e9092ee0f2ddbe8806d3ca3</citedby><cites>FETCH-LOGICAL-c4060-b2390590f3fae166e872d65155d9d2332838dd1fc3e9092ee0f2ddbe8806d3ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21073580$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khorsand, N.</creatorcontrib><creatorcontrib>Veeger, N. J. G. M.</creatorcontrib><creatorcontrib>Muller, M.</creatorcontrib><creatorcontrib>Overdiek, J. W. P. M.</creatorcontrib><creatorcontrib>Huisman, W.</creatorcontrib><creatorcontrib>van Hest, R. M.</creatorcontrib><creatorcontrib>Meijer, K.</creatorcontrib><title>Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy</title><title>Transfusion medicine (Oxford, England)</title><addtitle>Transfus Med</addtitle><description>Background: Although prothrombin complex concentrate (PCC) is often used to counteract vitamin K antagonist (VKA) therapy, evidence regarding the optimal dose for this indication is lacking. In Dutch hospitals, either a variable dose, based on body weight, target INR (international normalised ratio) and initial INR, or a fixed dose is used. Aim/objectives: In this observational, pilot study, the efficacy and feasibility of the fixed dose strategy compared to the variable dosing regimen, is investigated. Materials and Methods: Consecutive patients receiving PCC (Cofact®, Sanquin, Amsterdam) for VKA reversal because of a major non‐cranial bleed or an invasive procedure were enrolled in two cohorts. Data were collected prospectively in the fixed dose group, cohort 1, and retrospectively in the variable dose regimen, cohort 2. Study endpoints were proportion of patients reaching target INR and successful clinical outcome. Results: Cohort 1 consisted of 35 and cohort 2 of 32 patients. Target INR was reached in 70% of patients in cohort 1 versus 81% in cohort 2 (P = 0·37). Successful clinical outcome was seen in 91% of patients in cohort 1 versus 94% in cohort 2 (P = 1·00). Median INR decreased from 4·7 to 1·8 with a median dosage of 1040 IU factor IX (F IX) in cohort 1 and from 4·7 to 1·6 with a median dosage of 1580 IU F IX in cohort 2. Conclusion: This study suggests that a fixed dose of 1040 IU of F IX may be an effective way to rapidly counteract VKA therapy in our patient population and provides a basis for future research.</description><subject>Acenocoumarol - adverse effects</subject><subject>Acenocoumarol - antagonists &amp; inhibitors</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - antagonists &amp; inhibitors</subject><subject>Antidotes - administration &amp; dosage</subject><subject>Antidotes - therapeutic use</subject><subject>bleeding</subject><subject>Blood Coagulation Factors - administration &amp; dosage</subject><subject>Blood Coagulation Factors - therapeutic use</subject><subject>Cofact</subject><subject>Cohort Studies</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Hemorrhage - chemically induced</subject><subject>Hemorrhage - prevention &amp; control</subject><subject>Humans</subject><subject>International Normalized Ratio</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phenprocoumon - adverse effects</subject><subject>Phenprocoumon - antagonists &amp; inhibitors</subject><subject>Prospective Studies</subject><subject>prothrombin complex concentrate</subject><subject>Retrospective Studies</subject><subject>Vitamin K - antagonists &amp; inhibitors</subject><subject>vitamin K antagonist</subject><subject>Warfarin - adverse effects</subject><subject>Warfarin - antagonists &amp; inhibitors</subject><issn>0958-7578</issn><issn>1365-3148</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqNkE2P0zAQhi0EYsvCX0C-cUrxxzqxDxzQalvQduFSQOJiOfFk1yWJi-2U9N_jbJeesWTNjOd9Z6wHIUzJkubzfrekvBQFp1dyyUh-zVeQ5fQMLc6N52hBlJBFJSp5gV7FuCOEcqbYS3TBKKm4kGSBupWbwOIDhDhGfDDBmboDbH0E7Fu8Dz49BN_XbsCN7_cdTDkODQwpmAS49SHX45AgmCa54R4fXDJ9Vt9iMyRz7wcXE04Pub8_vkYvWtNFePMUL9G31c32-lOx-br-fP1xUzRXpCRFzbgiQpGWtwZoWYKsmC0FFcIqyzhnkktradtwUEQxANIya2uQkpSWN4Zfonenufn7v0eISfcuNtB1ZgA_Ri0FU6RUimalPCmb4GMM0Op9cL0JR02JnlHrnZ6J6pmonlHrR9R6yta3T0vGugd7Nv5jmwUfToI_roPjfw_W27ubOcv-4uTPBGE6-034pcuKV0L_-LLW32-3_OdqvdEb_hdiq54k</recordid><startdate>201104</startdate><enddate>201104</enddate><creator>Khorsand, N.</creator><creator>Veeger, N. J. G. M.</creator><creator>Muller, M.</creator><creator>Overdiek, J. W. P. M.</creator><creator>Huisman, W.</creator><creator>van Hest, R. M.</creator><creator>Meijer, K.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201104</creationdate><title>Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy</title><author>Khorsand, N. ; Veeger, N. J. G. M. ; Muller, M. ; Overdiek, J. W. P. M. ; Huisman, W. ; van Hest, R. M. ; Meijer, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4060-b2390590f3fae166e872d65155d9d2332838dd1fc3e9092ee0f2ddbe8806d3ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acenocoumarol - adverse effects</topic><topic>Acenocoumarol - antagonists &amp; inhibitors</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - antagonists &amp; inhibitors</topic><topic>Antidotes - administration &amp; dosage</topic><topic>Antidotes - therapeutic use</topic><topic>bleeding</topic><topic>Blood Coagulation Factors - administration &amp; dosage</topic><topic>Blood Coagulation Factors - therapeutic use</topic><topic>Cofact</topic><topic>Cohort Studies</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Hemorrhage - chemically induced</topic><topic>Hemorrhage - prevention &amp; control</topic><topic>Humans</topic><topic>International Normalized Ratio</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phenprocoumon - adverse effects</topic><topic>Phenprocoumon - antagonists &amp; inhibitors</topic><topic>Prospective Studies</topic><topic>prothrombin complex concentrate</topic><topic>Retrospective Studies</topic><topic>Vitamin K - antagonists &amp; inhibitors</topic><topic>vitamin K antagonist</topic><topic>Warfarin - adverse effects</topic><topic>Warfarin - antagonists &amp; inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khorsand, N.</creatorcontrib><creatorcontrib>Veeger, N. J. G. M.</creatorcontrib><creatorcontrib>Muller, M.</creatorcontrib><creatorcontrib>Overdiek, J. W. P. M.</creatorcontrib><creatorcontrib>Huisman, W.</creatorcontrib><creatorcontrib>van Hest, R. M.</creatorcontrib><creatorcontrib>Meijer, K.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion medicine (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khorsand, N.</au><au>Veeger, N. J. G. M.</au><au>Muller, M.</au><au>Overdiek, J. W. P. M.</au><au>Huisman, W.</au><au>van Hest, R. M.</au><au>Meijer, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy</atitle><jtitle>Transfusion medicine (Oxford, England)</jtitle><addtitle>Transfus Med</addtitle><date>2011-04</date><risdate>2011</risdate><volume>21</volume><issue>2</issue><spage>116</spage><epage>123</epage><pages>116-123</pages><issn>0958-7578</issn><eissn>1365-3148</eissn><abstract>Background: Although prothrombin complex concentrate (PCC) is often used to counteract vitamin K antagonist (VKA) therapy, evidence regarding the optimal dose for this indication is lacking. In Dutch hospitals, either a variable dose, based on body weight, target INR (international normalised ratio) and initial INR, or a fixed dose is used. Aim/objectives: In this observational, pilot study, the efficacy and feasibility of the fixed dose strategy compared to the variable dosing regimen, is investigated. Materials and Methods: Consecutive patients receiving PCC (Cofact®, Sanquin, Amsterdam) for VKA reversal because of a major non‐cranial bleed or an invasive procedure were enrolled in two cohorts. Data were collected prospectively in the fixed dose group, cohort 1, and retrospectively in the variable dose regimen, cohort 2. Study endpoints were proportion of patients reaching target INR and successful clinical outcome. Results: Cohort 1 consisted of 35 and cohort 2 of 32 patients. Target INR was reached in 70% of patients in cohort 1 versus 81% in cohort 2 (P = 0·37). Successful clinical outcome was seen in 91% of patients in cohort 1 versus 94% in cohort 2 (P = 1·00). Median INR decreased from 4·7 to 1·8 with a median dosage of 1040 IU factor IX (F IX) in cohort 1 and from 4·7 to 1·6 with a median dosage of 1580 IU F IX in cohort 2. Conclusion: This study suggests that a fixed dose of 1040 IU of F IX may be an effective way to rapidly counteract VKA therapy in our patient population and provides a basis for future research.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21073580</pmid><doi>10.1111/j.1365-3148.2010.01050.x</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0958-7578
ispartof Transfusion medicine (Oxford, England), 2011-04, Vol.21 (2), p.116-123
issn 0958-7578
1365-3148
language eng
recordid cdi_proquest_miscellaneous_852906991
source Wiley
subjects Acenocoumarol - adverse effects
Acenocoumarol - antagonists & inhibitors
Adult
Aged
Aged, 80 and over
Anticoagulants - adverse effects
Anticoagulants - antagonists & inhibitors
Antidotes - administration & dosage
Antidotes - therapeutic use
bleeding
Blood Coagulation Factors - administration & dosage
Blood Coagulation Factors - therapeutic use
Cofact
Cohort Studies
Dose-Response Relationship, Drug
Female
Hemorrhage - chemically induced
Hemorrhage - prevention & control
Humans
International Normalized Ratio
Male
Middle Aged
Phenprocoumon - adverse effects
Phenprocoumon - antagonists & inhibitors
Prospective Studies
prothrombin complex concentrate
Retrospective Studies
Vitamin K - antagonists & inhibitors
vitamin K antagonist
Warfarin - adverse effects
Warfarin - antagonists & inhibitors
title Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A32%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fixed%20versus%20variable%20dose%20of%20prothrombin%20complex%20concentrate%20for%20counteracting%20vitamin%20K%20antagonist%20therapy&rft.jtitle=Transfusion%20medicine%20(Oxford,%20England)&rft.au=Khorsand,%20N.&rft.date=2011-04&rft.volume=21&rft.issue=2&rft.spage=116&rft.epage=123&rft.pages=116-123&rft.issn=0958-7578&rft.eissn=1365-3148&rft_id=info:doi/10.1111/j.1365-3148.2010.01050.x&rft_dat=%3Cproquest_cross%3E852906991%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4060-b2390590f3fae166e872d65155d9d2332838dd1fc3e9092ee0f2ddbe8806d3ca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=852906991&rft_id=info:pmid/21073580&rfr_iscdi=true